| 2000-02 |
大学発スタートアップとして神奈川県横浜市に株式会社レナサイエンスを設立 |
| 2000-02 |
Founded Renascience Inc. as an academic bio-venture company in Kanagawa, Japan |
| 2021-09 |
東京証券取引所マザーズ市場（現：グロース市場）に株式上場（証券コード：4889） |
| 2021-09 |
Listed on the Tokyo Stock Exchange Mothers market (current Growth market, securities code: 4889) |
| 2022-01 |
東北大学レナサイエンスオープンイノベーションラボ（TREx）開設 |
| 2022-01 |
Open Tohoku University Renascience Open Innovation Labo (TREx) |
| 2022-08 |
慢性骨髄性白血病の第Ⅲ相試験を開始 |
| 2022-08 |
Initiation of dosing in a PhaseⅢ study of chronic myeloid leukemia |
| 2022-12 |
ディスポーザブル極細内視鏡の薬事承認 |
| 2022-12 |
Regulatory Approval of Ultrafine Disposable Endoscope |
| 2023-04 |
広島大学レナサイエンスオープンイノベーションラボ（HiREx）開設 HiREx = Hiroshima University x Renascience |
| 2023-04 |
Open Hiroshima University Renascience Open Innovation Labo (HiREx) |
| 2023-08 |
悪性黒色腫の第Ⅱ相試験におけるPOC取得 |
| 2023-08 |
Obtained POC in Phase II study for malignant melanoma |
| 2023-09 |
非小細胞肺がん治療薬の第II相試験を開始 |
| 2023-09 |
Initiation of Phase II Study for Non-Small Cell Lung Cancer |
| 2023-10 |
全身性強皮症に伴う間質性肺疾患治療薬の第II相試験を開始 |
| 2023-10 |
皮膚血管肉腫治療薬の第II相試験を開始 |
| 2023-10 |
Initiation of Phase II Study for interstitial lung disease associated with systemic scleroderma |
| 2023-10 |
Initiation of Phase II Study for Cutaneous Angiosarcoma |
| 2023-10 |
Initiation of Phase II study for interstitial lung disease associated with systemic scleroderma |
| 2024-07 |
Eirion社における男性型脱毛症 (加齢性脱毛症)の第Ⅰ相臨床試験開始 |
| 2024-07 |
Initiation of Phase I clinical trial for male pattern baldness (age-related alopecia) by Eirion inc. |
| 2024-09 |
悪性黒色腫治療薬の厚生労働省希少疾患用医薬品指定 |
| 2024-09 |
Rare disease drug designation for malignant melanoma treatment drug |
| 2024-10 |
東京中央区日本橋より宮城県仙台市へ本社移転 |
| 2024-10 |
Relocated its head office from Nihonbashi, Chuo-ku, Tokyo to Sendai City, Miyagi Prefecture. |
| 2025-02 |
悪性黒色腫の第Ⅲ相試験を開始 |
| 2025-02 |
initiation of the Phase III trial of malignant melanoma treatment drug RS5614 |
| 2025-05 |
世界的長寿研究コンペティションXPRIZE HealthspanのTOP40入賞 |
| 2025-05 |
Top 40 winner of the XPRIZE Healthspan, a global longevity research competition |
| 2025-11 |
第三者割当による新株式及び新株予約権の発行 |
| 2025-11 |
Issuance of new shares and stock acquisition rights through third-party allotment |
| 2025-11 |
第1回第三者割当による新株式及び新株予約権の発行 |
| 2025-11 |
Issuance of new shares and stock acquisition rights through the 1st third-party allotment |
| 2025-12 |
第2回第三者割当による新株式及び新株予約権の発行 |
| 2025-12 |
Issuance of new shares and stock acquisition rights through the 2nd third-party allotment |
| 2026-02 |
第3回第三者割当による新株式及び新株予約権の発行 |
| 2026-02 |
Issuance of new shares and stock acquisition rights through the 3rd third-party allotment |
| 2026-03 |
第4回第三者割当による新株式及び新株予約権の発行 |
| 2026-03 |
Issuance of new shares and stock acquisition rights through the 4th third-party allotment |
| 2026-04 |
非小細胞肺がんの後期第Ⅱ相試験開始 |
| 2026-05 |
膵臓がんの第Ⅱ相試験開始 |
| 2026-05 |
Initiation of a Phase II Trial for Pancreatic Cancer |
| 2026-08 |
Initiation of a phase II trial for locally advanced non-small cell lung cancer |
